| Literature DB >> 33688217 |
Ayan Aden Moussa1,2, Abdkerem Abdulahi Abdi1,2, Mohamed Abdullahi Awale1,2, Bashiru Garba3.
Abstract
PURPOSE: This study reports a cross-sectional investigation to determine the antimicrobial resistance pattern of the common bacterial contaminants isolated from hospitalized patients in Mogadishu, Somalia.Entities:
Keywords: Somalia; antimicrobial resistance; hygiene; multidrug-resistant pathogens; nosocomial infection; sanitation
Year: 2021 PMID: 33688217 PMCID: PMC7936673 DOI: 10.2147/IDR.S275090
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Prevalence of bacterial species isolated from positive cultures according to gender.
Figure 2Illustration of bacterial growth from samples analyzed according to age category.
Antimicrobial Susceptibility/Resistance Pattern of Bacterial Isolates
| Antimicrobial Agent | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suscept. (%) | Resist. (%) | Suscept. (%) | Resist. (%) | Suscept. (%) | Resist. (%) | Suscept. (%) | Resist. (%) | Suscept. (%) | Resist. (%) | Suscept. (%) | Resist. (%) | |
| Amoxicillin (AUG) | 140 (92.1) | 12 (7.9) | 56 (93.3) | 4 (3.7) | 8 (80) | 2 (20) | 5 (83.3) | 1 (6.7) | 27 (96.4) | 1 (3.6) | 1 (100) | 0 (0) |
| Cefuroxime (CXM) | 152 (100) | 0 (0) | 60 (100) | 0 (0) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Gentamycin (CN) | 148 (97.4) | 4 (2.6) | 60 (100) | 0 (0) | 10 (100) | 0 (0) | 5 (83.3) | 1 (6.7) | 27 (96.4) | 1 (3.6) | 1 (100) | 0 (0) |
| Ciprofloxacin (CIP) | 140 (92.1) | 12 (7.9) | 56 (93.3) | 4 (3.7) | 9 (90) | 1 (10) | 5 (83.3) | 1 (6.7) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Nitrofurantoin (F) | 143 (94.1) | 9 (5.9) | 59 (98.3) | 1 (1.7) | 8 (80) | 2 (20) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Trimetho/Sulph (SXT) | 152 (100) | 0 (0) | 60 (100) | 0 (0) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Norfloxacin (NOR) | 152 (100) | 0 (0) | 60 (100) | 0 (0) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Nalidixic acid (NAL) | 152 (100) | 0 (0) | 60 (100) | 0 (0) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Ceftazidime (CAZ) | 146 (96.1) | 6 (3.9) | 58 (96.7) | 2 (3.3) | 9 (90) | 1 (10) | 5 (83.3) | 1 (6.7) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Meropenem (MEM) | 152 (100) | 0 (0) | 60 (100) | 0 (0) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Amikacin (AK) | 152 (100) | 0 (0) | 59 (98.3) | 1 (1.7) | 9 (90) | 1 (10) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Levofloxacin (LEV) | 139 (91.5) | 13 (8.5) | 55 (91.7) | 5 (8.3) | 10 (100) | 0 (0) | 5 (83.3) | 1 (6.7) | 25 (89.3) | 3 (10.7) | 0 (0) | 1 (100) |
| Clindamycin (CD) | 124 (81.6) | 28 (18.4) | 56 (93.3) | 4 (3.7) | 10 (100) | 0 (0) | 5 (83.3) | 1 (6.7) | 22 (78.6) | 6 (21.4) | 0 (0) | 1 (100) |
| Linezolid (LNZ) | 148 (97.4) | 4 (2.6) | 57 (95) | 3 (5) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 25 (89.3) | 3 (10.7) | 0 (0) | 1 (100) |
| Vancomycin (VA) | 133 (87.5) | 19 (12.5) | 57 (95) | 3 (5) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 25 (89.3) | 3 (10.7) | 0 (0) | 1 (100) |
| Ampicillin (AMP) | 137 (90.1) | 15 (9.9) | 53 (83.3) | 7 (6.7) | 9 (90) | 1 (10) | 6 (100) | 0 (0) | 24 (85.7) | 4 (14.3) | 1 (100) | 0 (0) |
| Azithromycin (AZM) | 147 (96.7) | 5 (3.3) | 55 (91.7) | 5 (8.3) | 9 (90) | 1 (10) | 5 (83.3) | 1 (6.7) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Ceftriaxone (CRO) | 151 (99.3) | 1 (0.7) | 60 (100) | 0 | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
| Cefotaxime (CTX) | 146 (96.1) | 6 (3.9) | 57 (95) | 3 (5) | 10 (100) | 0 (0) | 6 (100) | 0 (0) | 28 (100) | 0 (0) | 1 (100) | 0 (0) |
Figure 3Distribution of multidrug-resistant bacterial isolates obtained from hospitalized patients in the hospital, Mogadishu, Somalia.